Research overview of GLP-1 agonists: how semaglutide, tirzepatide, and retatrutide differ on receptors, weight-loss data, and practical comparison points.
Last updated Jun 11, 2026·9 min read
In 2024, the Nobel Prize in Physiology or Medicine honored the discovery of GLP-1 — a gut hormone most people had never heard of and nearly everyone suddenly has an opinion about. The molecules built from it now anchor the most actively studied area in obesity and type 2 diabetes research. And the story begins with a strange biological irony: the body makes an elegantly precise appetite-and-glucose signal, then destroys it within two minutes.
That self-destruct timer shaped everything that followed. Native GLP-1 (glucagon-like peptide-1) is a 31-amino-acid incretin hormone released from intestinal L-cells when nutrients arrive. It stimulates insulin secretion from pancreatic beta cells only when blood glucose is elevated, while simultaneously suppressing glucagon release from alpha cells PMID: 37952131 — glucose-dependent action that separates it from blunt exogenous insulin, which keeps working even when glucose is normal. But the DPP-4 enzyme cleaves native GLP-1 within minutes of release, leaving a half-life of roughly 2 minutes in circulation. Every major advance since has been an engineering escape from that clock: longer exposure, stronger receptor engagement, broader metabolic reach.
Three compounds mark the frontier. **Semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization stretched the half-life to approximately one week and established once-weekly GLP-1 receptor agonism as viable therapy. Tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity added a second target — the GIP receptor — creating a dual agonist whose metabolic effects exceed GLP-1 activation alone. Retatrutide Retatrutide triple incretin receptor agonist (GLP-1/GIP/glucagon) Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease ** layered glucagon receptor agonism on top, producing a triple agonist behind the largest weight-loss figures reported in any clinical trial to date.
By the end of this guide you'll understand how each compound is engineered, what the headline trials actually measured — including what those percentages mean at a human scale — and where each sits in the regulatory landscape. One transparency note woven in here rather than repeated later: these are approved pharmaceuticals studied in regulated clinical trials; nothing below constitutes medical advice.
I.Overview
The incretin system is not one pathway but an integrated network coordinating what happens after a meal: glucose disposal, appetite regulation, energy metabolism. Two gut-derived hormones do most of the coordinating — GLP-1 and GIP — released when nutrients arrive and acting on receptors in the pancreas, brain, and peripheral tissues.
Their combined impact is larger than most people realize. In healthy individuals, the incretin effect — oral glucose triggering a far greater insulin response than intravenous glucose at matched blood concentrations — accounts for roughly 50–70% of post-meal insulin secretion PMID: 21984584 . In other words, more than half of the insulin released after dinner exists because gut hormones told the pancreas it was coming. That effect runs through GLP-1 and GIP acting on pancreatic beta cells to amplify glucose-stimulated insulin secretion.
GLP-1 receptor activation reaches well beyond insulin. In the hypothalamus and brainstem, GLP-1R signaling suppresses appetite by modulating POMC and CART neurons while inhibiting the hunger-promoting NPY and AgRP circuits PMID: 39728000 . In the stomach it slows gastric emptying, extending satiety. In liver and adipose tissue it activates AMPK/SIRT1 pathways associated with metabolic homeostasis and fat-cell browning.
GIP receptor agonism adds a complementary layer. GIP was long considered the lesser incretin — its insulinotropic effect weakens in type 2 diabetes — but recent work shows GIPR activation in adipose tissue improves lipid metabolism and nutrient partitioning through mechanisms independent of the pancreas PMID: 34003802 . GIPR signaling in the brain also appears to dampen the nausea commonly driven by GLP-1R activation, potentially permitting higher effective doses.
Glucagon receptor agonism looks like sabotage until you see the doses. Glucagon raises blood glucose — the opposite of diabetes therapy's goal. Yet in triple-agonism designs, GCGR activation stimulates hepatic fatty acid oxidation and energy expenditure, creating a catabolic liver signal that complements the glucose-lowering actions of GLP-1 and GIP PMID: 37366315 . That thermogenic component gives triple agonists their distinctive profile.
Single to dual to triple agonism therefore traces a deepening map of metabolic control, each receptor contributing what the others cannot. Whether added complexity yields proportional clinical benefit — with acceptable safety — is precisely the question driving current research.
Semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization is a masterclass in small changes compounding. A modified GLP-1 analogue, this 31-amino-acid peptide carries three structural edits that stretch its half-life from the native 2 minutes to about one week. An aminoisobutyric acid (Aib) substitution at position 8 blocks DPP-4 cleavage. An Arg34 substitution tunes receptor binding kinetics. And a C18 fatty diacid chain attached to lysine at position 26 binds serum albumin non-covalently, shielding the peptide from renal clearance and enzymatic attack PMID: 37952131 .
The result weighs 4,113.6 Da, circulates for approximately 168 hours, and supports once-weekly subcutaneous dosing. An oral formulation (Rybelsus) uses the absorption enhancer SNAC to push sufficient bioavailability through the gastrointestinal tract.
No GLP-1 receptor agonist has deeper clinical documentation. The STEP trial program enrolled over 17,000 participants across multiple phase 3 studies. STEP 1 reported mean body weight reduction of 14.9% at 68 weeks with once-weekly semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization 2.4 mg versus 2.4% with placebo PMID: 33567185 — for someone carrying 100 kg, that's roughly 15 kg lost versus about 2 kg on placebo. The SUSTAIN program in type 2 diabetes showed HbA1c reductions of 1.5–1.8% across studies, beating multiple active comparators along the way.
Then SELECT widened the story. In 2023, semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease — the first GLP-1 receptor agonist to demonstrate cardiovascular risk reduction in a non-diabetic populationPMID: 37952131 . Metabolic research stopped being only about weight that year.
The appetite mechanism runs centrally: hypothalamic GLP-1R activation shifts the balance between POMC/CART neurons (satiety) and NPY/AgRP neurons (hunger), reducing food intake PMID: 39728000 , with delayed gastric emptying reinforcing post-meal fullness — though that emptying effect may attenuate with chronic use. Under investigation too: NF-κB inhibition and anti-inflammatory macrophage modulation PMID: 39728000 , AMPK/SIRT1 activation with adipose browning, and SIRT1/NRF2 antioxidant signaling — hinting at cellular-level effects beyond appetite.
Regulatorily, semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization is unambiguous: FDA, EMA, and MHRA approval for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy), classified as Phase 4 post-marketing — the most mature compound in its class.
Tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity answers a question pure GLP-1 drugs couldn't: what if the forgotten incretin was worth engineering back in? A dual GIP/GLP-1 receptor agonist, this 39-amino-acid linear peptide derives from the native GIP sequence, modified so it activates both receptors simultaneously. A C-20 fatty diacid conjugated to lysine at position 20 provides albumin binding for extended half-life; an aminoisobutyric acid substitution at position 2 resists DPP-4 degradation PMID: 32730231 .
Molecular weight is 4,813.5 Da with a half-life near 5 days, dosed once weekly subcutaneously. Its amino acid sequence is publicly documented — unlike retatrutide Retatrutide triple incretin receptor agonist (GLP-1/GIP/glucagon) Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease 's, which remains proprietary.
**What separates tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity mechanistically is engineered imbalance.** It activates both receptors but skews toward GIPR engagement — deliberately. Its binding affinity and intracellular signaling produce greater GIPR-mediated effects relative to GLP-1R effects than equipotent dual agonism would predict PMID: 34003802 . The design bets that GIPR activation contributes underexploited metabolic benefits, particularly in adipose nutrient handling and insulin sensitization.
The clinical numbers carry real weight. SURPASS, in type 2 diabetes, delivered HbA1c reductions of 2.0–2.4% across studies and beat semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization 1 mg head-to-head [PMID: 34186022, PMID: 34370970]. SURMOUNT, in obesity, produced mean weight reductions of 15–22.5% depending on dose (5–15 mg) — the top dose translating to over 20 kg for someone starting at 100 kg, the largest loss recorded for any approved medication at publication PMID: 35133415 .
The quieter innovation is nausea management. Research suggests GIPR activation in brainstem nausea circuits partially counteracts the emetic drive of GLP-1R stimulation [PMID: 34844019, PMID: 34380697] — potentially allowing higher effective GLP-1R engagement without proportionally worse gastrointestinal side effects. Add weight-independent insulin sensitization and adipocyte metabolism modulation via GIPR [PMID: 34003802, PMID: 38878772], and tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity stands clearly apart from single-agonist drugs that improve metabolism mainly through weight loss itself.
Regulatory status mirrors semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization 's maturity: FDA approval as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), plus EMA and MHRA authorization, under active post-marketing surveillance.
Retatrutide Retatrutide triple incretin receptor agonist (GLP-1/GIP/glucagon) Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease is where the engineering paradigm currently ends. The first compound designed to activate GLP-1, GIP, and glucagon receptors with a single molecule, developed by Eli Lilly, it adds hepatic glucagon signaling to the incretin portfolio — and with it, a genuinely different metabolic flavor.
Its amino acid sequence remains proprietary. Half-life runs approximately 6 days, supporting once-weekly subcutaneous administration. Phase 3 development is underway; no regulatory agency has approved it.
Why add a receptor that raises blood sugar? Because hepatic glucagon receptor activation does things neither incretin can: stimulates fatty acid oxidation, increases energy expenditure, promotes lipolysis PMID: 37366315 . At triple-agonism doses the net effect is a catabolic liver signal amplifying overall metabolic impact beyond what GLP-1 and GIP achieve together.
The Phase 2 data made the field recalibrate. Mean body weight reductions reached 24.2% at 48 weeks at the highest dose (12 mg weekly) PMID: 37366315 — someone entering at 100 kg would lose on the order of 24 kg, the largest figure reported for any anti-obesity medication candidate at publication, exceeding semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization 2.4 mg and tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity 15 mg in cross-trial comparison (though no head-to-head trial has run).
Cardiometabolic markers moved too. Liver fat fell by up to 80% in participants with metabolic dysfunction-associated steatotic liver disease PMID: 37385280 , suggesting relevance for a condition with few treatment options, and HbA1c dropped by up to 2.0% in participants with type 2 diabetes.
Safety tracked the class pattern: gastrointestinal events — nausea, diarrhea, constipation — led the list, generally mild-to-moderate and concentrated during dose escalation, with no clinically significant hyperglycemia attributable to the glucagon arm, consistent with GLP-1/GIP offsetting glucagon's glucose-raising tendency.
Multiple Phase 3 trials (the TRIUMPH program) are evaluating retatrutide Retatrutide triple incretin receptor agonist (GLP-1/GIP/glucagon) Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease for obesity, type 2 diabetes, and MASH. If those results confirm Phase 2, retatrutide would step into trials as the most potent weight-management medication in clinical development — and the open question becomes whether quadruple designs will try to push further. For now it remains investigational: not approved by the FDA, EMA, or MHRA, restricted to trial settings, and — as a proprietary compound — unavailable as research-grade material in the way preclinical-stage peptides are.
GLP-1 (glucagon-like peptide-1) is a 31-amino-acid incretin hormone released from intestinal L-cells when nutrients arrive. It stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through central nervous system pathways. Its defining safety feature is glucose-dependence: no insulin release when glucose is already normal. Native GLP-1 survives only ~2 minutes against DPP-4 cleavage — the instability that motivated long-acting analogues like semaglutide [PMID: 37952131].
Receptor breadth is the difference, and each receptor earns its place. Semaglutide activates only the GLP-1 receptor. Tirzepatide targets GIP and GLP-1 receptors together, with engineered bias toward GIPR engagement rather than equal dual agonism [PMID: 34003802]. Retatrutide adds the glucagon receptor to both [PMID: 37366315]. Each receptor contributes distinct effects: GLP-1R for insulin secretion and appetite suppression, GIPR for adipose tissue metabolism and nausea attenuation, GCGR for hepatic fatty acid oxidation and energy expenditure.
From their pivotal trials: semaglutide 2.4 mg produced mean weight loss of 14.9% at 68 weeks in STEP 1 [PMID: 33567185]; tirzepatide 15 mg produced 22.5% at 72 weeks in SURMOUNT-1 [PMID: 35133415]; retatrutide 12 mg produced 24.2% at 48 weeks in Phase 2 [PMID: 37366315]. At a human scale, those figures mean roughly 15 kg, 22 kg, and 24 kg respectively for someone starting at 100 kg — differences that compound meaningfully over a year. Cross-trial comparisons demand caution given differing designs, populations, and durations — but the trend favoring broader receptor agonism holds steady across every generation.
Because context changes everything. Glucagon raises blood glucose — the apparent dealbreaker for a diabetes drug. But in triple agonism its glucose-elevating action is offset by the insulinotropic effects of GLP-1 and GIP signaling, so hyperglycemia never materializes clinically. What survives is glucagon's catabolic side: hepatic fatty acid oxidation, increased energy expenditure, promoted lipolysis [PMID: 37366315]. That thermogenic dimension adds a metabolic lever GLP-1 and GIP alone don't provide — and it's hypothesized to explain much of retatrutide's superior weight-loss signal.
SELECT (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — by 20% versus placebo in adults with overweight or obesity and established cardiovascular disease, regardless of diabetes status [PMID: 37952131]. It was the first demonstration of cardiovascular risk reduction by a GLP-1 receptor agonist in a non-diabetic population, recasting the entire drug class as potential cardioprotection beyond glucose and weight.
Head-to-head in SURPASS-2, tirzepatide (5–15 mg) achieved greater HbA1c reduction than semaglutide 1 mg in type 2 diabetes [PMID: 34186022]. In obesity, cross-trial comparisons suggest tirzepatide 15 mg produces roughly 7–8 percentage points more weight loss than semaglutide 2.4 mg. The edge is attributed to GIPR-mediated adipose metabolism benefits, weight-independent insulin sensitization [PMID: 38878772], and GIPR signaling's anti-nausea properties enabling higher effective GLP-1R engagement [PMID: 34844019].
Gastrointestinal events dominate, and they're class effects rather than quirks of one molecule: nausea, diarrhea, vomiting, constipation — worst during dose escalation, generally mild-to-moderate in severity, and fading with continued use. The nausea component runs primarily through GLP-1R activation in brainstem circuits. Tirzepatide's GIPR arm appears to partially counteract it [PMID: 34380697], which is part of that compound's design logic. Retatrutide's Phase 2 safety profile resembles the class broadly, with no unique safety signals identified.
Two of the three are fully approved pharmaceuticals with established regulatory pathways. Semaglutide and tirzepatide hold FDA, EMA, and MHRA approvals for type 2 diabetes and chronic weight management, supported by large phase 3 programs. Retatrutide is investigational only — available exclusively inside clinical trial settings. None belong to the research-chemical category occupied by preclinical-stage peptides like BPC-157 or TB-500; they're regulated medicines, which is precisely why their evidence bases run so much deeper.
Retatrutide leads the pipeline as the most advanced triple agonist in clinical development, with TRIUMPH Phase 3 trials running for obesity, type 2 diabetes, and MASH. Other pharmaceutical companies are developing their own multi-receptor agonists, though most remain in earlier clinical stages. The open design question is whether triple agonism represents the optimal receptor combination or whether amylin and PYY receptors join future molecules for even broader metabolic coverage. The field moves quickly — expect new clinical data continuously through 2026–2028.
Start with PubMed, the National Library of Medicine's database — searching 'semaglutide,' 'tirzepatide,' or 'retatrutide' returns thousands of studies. Key PubMed IDs referenced in this guide include [PMID: 37952131] and [PMID: 33567185] for semaglutide; [PMID: 32730231], [PMID: 34003802], and [PMID: 35133415] for tirzepatide; and [PMID: 37366315] and [PMID: 37385280] for retatrutide. SELECT results appear in [PMID: 37952131]. Approved prescribing information lives in the FDA's DailyMed label database for semaglutide and tirzepatide products.
V.Summary
Semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization , tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity , and retatrutide Retatrutide triple incretin receptor agonist (GLP-1/GIP/glucagon) Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease form three generations of one engineering idea — each generation adding receptors and each adding metabolic effect. Semaglutide validated once-weekly GLP-1 agonism. Tirzepatide proved GIP activation could surpass it. Retatrutide showed glucagon agonism could push further still.
The clinical evidence describes a dose-response relationship between receptor breadth and metabolic potency: single to dual to triple agonism has yielded incrementally greater weight loss and glycemic improvement across trials. Where the ceiling sits — or whether amylin or PYY receptors get recruited into future designs — remains open.
The cardiovascular dimension may prove just as consequential. SELECT demonstrated semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization reduces MACE in non-diabetic adults with obesity, establishing GLP-1 agonism as a cardioprotective intervention category. Whether dual and triple agonists match or exceed that benefit through their broader profiles is exactly what ongoing trials aim to settle.
For researchers evaluating these compounds, the primary literature — peer-reviewed studies indexed in PubMed — remains authoritative. Key PubMed IDs referenced in this guide include PMID: 37952131 and PMID: 33567185 for semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization ; PMID: 32730231 , PMID: 34003802 , and PMID: 35133415 for tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity ; and PMID: 37366315 and PMID: 37385280 for retatrutide Retatrutide triple incretin receptor agonist (GLP-1/GIP/glucagon) Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease .
For compound-vs-compound analysis, see [Semaglutide Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization vs Tirzepatide Tirzepatide dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist Dual GIP/GLP-1 receptor agonist studied for type 2 diabetes and obesity ](/en/compare/semaglutide-vs-tirzepatide/) and [Retatrutide Retatrutide triple incretin receptor agonist (GLP-1/GIP/glucagon) Triple receptor agonist (GLP-1/GIP/glucagon) studied for obesity, type 2 diabetes, and metabolic disease vs Semaglutide](/en/compare/retatrutide-vs-semaglutide-weight/). For these molecules alongside other metabolic peptides, see the Weight Loss Peptides Guide.
Tirzepatide 
Retatrutide 
Semaglutide GLP-1 receptor agonist (incretin mimetic) GLP-1 receptor agonist for appetite regulation and metabolic optimization is a masterclass in small changes compounding. A modified GLP-1 analogue, this 31-amino-acid peptide carries three structural edits that stretch its half-life from the native 2 minutes to about one week. An aminoisobutyric acid (Aib) substitution at position 8 blocks DPP-4 cleavage. An Arg34 substitution tunes receptor binding kinetics. And a C18 fatty diacid chain attached to lysine at position 26 binds serum albumin non-covalently, shielding the peptide from renal clearance and enzymatic attack PMID: 37952131 .